August 28, 2017

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative Director and President
(TSE Mothers Code:4592)
Contact: Yoshihiro Kakutani, Corporate Officer of Management Administration
(TEL.+81-3-6264-3481)

(Delayed) Summary of Procurement of Funds for Development in the Current Fiscal Year

The Group (hereafter referring to both SanBio Co., Ltd. as "the Company," and its subsidiary SanBio, Inc.) procured funds three times up to last week in the current fiscal year (from February 1, 2017 to January 31, 2018), which has been sorted and summarized as shown below.

The Group has been developing regenerative cell therapies and is engaged in research, development and manufacture of cell medicines for central nervous system diseases using stem cells. Currently, the Company is conducting a Phase 2b clinical trial of its unique regenerative cell medicine SB623 for the treatment of chronic disabilities resulting from stroke as a target indication in the US together with its joint development partner Sumitomo Dainippon Pharma Co., Ltd. In addition, the Company is independently conducting a Phase 2 clinical trial for the treatment of chronic disabilities resulting from traumatic brain injury in both the US and Japan.

The funds procured totaled ¥4,700 million and will be allocated to the Phase 2 clinical trial for the treatment of chronic traumatic brain injury and the Phase 2b clinical trial for the treatment of chronic stroke. Consequently, funds for development have been covered appropriately at present.

<Overview of funds procured in the current fiscal year>

Contracting party	Form of funding	Amount of funds procured	Date of agreement (or date of approval)	Use of funds
Mitsubishi UFJ Trust and Banking Corporation	Borrowing	¥900 million	March 2017	Chronic stroke in the US and chronic traumatic brain injury in the US and Japan
California Institute of Regenerative Medicine (CIRM)	Grant	$20 million (¥2,200 million)*	June 2017	Chronic stroke in the US
Mizuho Bank, Ltd.	Commitment line	¥1,600 million	August 2017	Cash in reserve for chronic traumatic brain injury
		Total ¥4,700 million		

*Exchange rate: $1 = ¥110

The Company will continue to consider procurement of funds in order to maintain and secure stable funding. In the event that any additional procurement of funds is resolved in the future, the Company will promptly announce the details.